Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 July 2021Website:
http://www.ranitherapeutics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 21:24:34 GMTDividend
Analysts recommendations
Institutional Ownership
RANI Latest News
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:
Rani Therapeutics Holdings, Inc. has an exciting oral drug delivery system for biologics. It has shown excellent early data in trials.
What type of business is Rani Therapeutics Holdings?
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
What sector is Rani Therapeutics Holdings in?
Rani Therapeutics Holdings is in the Healthcare sector
What industry is Rani Therapeutics Holdings in?
Rani Therapeutics Holdings is in the Biotechnology industry
What country is Rani Therapeutics Holdings from?
Rani Therapeutics Holdings is headquartered in United States
When did Rani Therapeutics Holdings go public?
Rani Therapeutics Holdings initial public offering (IPO) was on 30 July 2021
What is Rani Therapeutics Holdings website?
https://www.ranitherapeutics.com
Is Rani Therapeutics Holdings in the S&P 500?
No, Rani Therapeutics Holdings is not included in the S&P 500 index
Is Rani Therapeutics Holdings in the NASDAQ 100?
No, Rani Therapeutics Holdings is not included in the NASDAQ 100 index
Is Rani Therapeutics Holdings in the Dow Jones?
No, Rani Therapeutics Holdings is not included in the Dow Jones index
When does Rani Therapeutics Holdings report earnings?
The next expected earnings date for Rani Therapeutics Holdings is 09 August 2024